Get it on Google Play

BridgeBio to present encaleret trial data at ASBMR 2026 meeting

October 6, 2026 4:01 PM EDT Send to a Friend
BridgeBio Pharma (Nasdaq: BBIO) will present data from its Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login